Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promising Topline Results for Intralymphatic Diamyd® in Patients With LADA
Details : Primary endpoints of safety and tolerability were met in Phase II clinical trial GADinLADA, in which diabetes vaccine Diamyd (GAD-alum) was administered directly into lymph node of 14 patients aged 30 to 70 years with autoimmune form of diabetes called L...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical AB Fully Recruited Patients in Clinical Trial with Diamyd®
Details : The clinical Phase II trial GADinLADA, where the diabetes vaccine Diamyd® is administered directly into the lymph node in patients with the autoimmune form of diabetes LADA, is fully recruited, and the first results from the trial are planned to be anno...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
September 04, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd® Phase IIb trial results published in Diabetes Care
Details : The patients, diagnosed with type 1 diabetes, have been given the diabetes vaccine Diamyd® directly into the lymph node on three occasions, one month apart, in combination with oral vitamin D (or its placebo) during four months, starting 30 days prior t...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
May 21, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : All 50 patients who participated in the extension of Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd® have now made their 24-month visit, and data will be presented in early July.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Update on the Design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd®
Details : The trial is designed to confirm the effect and safety of Diamyd® in individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
April 03, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical To Present at Upcoming Scientific Conferences
Details : Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DIAGNODE-2 Results and Meta-Analysis with Diamyd® to Be Presented at Diabetes Conference
Details : Results from the phase IIb trial DIAGNODE-2 with intralymphatic administration of Diamyd® and meta-analysis comprising data from more than 600 patients treated with Diamyd® showing treatment effect in individuals carrying the HLA DR3-DQ2 haplotype, wil...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
February 26, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Diamyd Medical Elected to Present Diamyd® Meta-Analysis Results at the EASD Diabetes Conference
Details : The results support a precision medicine approach with Diamyd® where significant effect on the preservation of endogenous insulin producing capacity and improved blood glucose control was seen in individuals that carry a specific genotyp, HLA DR3-DQ2.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
February 06, 2021
Lead Product(s) : GAD-alum,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The immunological findings indicate early treatment-specific immune responses that may associate with HLA type and clinical treatment response to Diamyd®.
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : GAD-alum
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GAD-alum
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd is expected to present Topline results at the end of September. All patients in the trial where Diamyd® is given directly into the lymph node have completed their 15-month vis...
Product Name : Diamyd
Product Type : Vaccine
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : GAD-alum
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable